Drugs / irbesartanhydrochlorothiazide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | IRBESARTAN AND HYDROCHLOROTHIAZIDE | — | 2012-09-27 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00264212 | Aug 2004 → ? | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT05552300 Background | Oct 2022 → Oct 2024 | resistant hypertension | First Affiliated Hospital of Chengdu Medical College | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | irbesartanhydrochlorothiazide | “irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d” NCT05552300 ↗ |